Search research articles
Contact Us
Filters
Showing results (681-690 of 718) with videos related to
Page
of 72
Sort By:
The Journal of Hospital Infection
|
April 24, 2017
Multi-state survey of healthcare-associated infections in acute care hospitals in Brazil
C Magno Castelo Branco Fortaleza, M C Padoveze, C R Veiga Kiffer, et al.
Journal of Medicinal Chemistry
|
October 3, 2003
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants
Patrick Y S Lam, Charles G Clark, Renhua Li, et al.
Life Sciences
|
September 30, 2021
TLR4 deletion increases basal energy expenditure and attenuates heart apoptosis and ER stress but mitigates the training-induced cardiac function and performance improvement
Larissa G de Vicente, Vitor R Muñoz, Ana P Pinto, et al.
Hormones & Cancer
|
November 23, 2018
Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective
Mauricio P Pinto, Matías Muñoz Medel, Diego Carrillo, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 22, 2008
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties
James R Corte, Tianan Fang, Donald J P Pinto, et al.
Pflugers Archiv : European Journal of Physiology
|
January 13, 2025
Combined exercise-induced modulation of Notch pathway and muscle quality in senescence-accelerated mice
Ana P Pinto, Ângelo Augusto J Sarni, Maria Eduarda A Tavares, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
Donald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
Scientific Reports
|
August 3, 2017
Structural and functional identification of vasculogenic mimicry in vitro
Dusan Racordon, Andrés Valdivia, Gabriel Mingo, et al.
Clinical and Experimental Pharmacology & Physiology
|
October 30, 2024
Short-term exercise counteracts accelerated ageing impacts on physical performance and liver health in mice
Ana P Pinto, Vitor R Muñoz, Maria Eduarda A Tavares, et al.
Journal of Cellular Physiology
|
March 12, 2014
Independent anti-angiogenic capacities of coagulation factors X and Xa
Soledad Lange, Ibeth Gonzalez, Mauricio P Pinto, et al.
Page
of 72
Search research articles
Search
Showing results (681-690 of 718) with videos related to
Sort By:
Page
of 72
The Journal of Hospital Infection
|
April 24, 2017
Multi-state survey of healthcare-associated infections in acute care hospitals in Brazil
C Magno Castelo Branco Fortaleza, M C Padoveze, C R Veiga Kiffer, et al.
Journal of Medicinal Chemistry
|
October 3, 2003
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants
Patrick Y S Lam, Charles G Clark, Renhua Li, et al.
Life Sciences
|
September 30, 2021
TLR4 deletion increases basal energy expenditure and attenuates heart apoptosis and ER stress but mitigates the training-induced cardiac function and performance improvement
Larissa G de Vicente, Vitor R Muñoz, Ana P Pinto, et al.
Hormones & Cancer
|
November 23, 2018
Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective
Mauricio P Pinto, Matías Muñoz Medel, Diego Carrillo, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 22, 2008
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties
James R Corte, Tianan Fang, Donald J P Pinto, et al.
Pflugers Archiv : European Journal of Physiology
|
January 13, 2025
Combined exercise-induced modulation of Notch pathway and muscle quality in senescence-accelerated mice
Ana P Pinto, Ângelo Augusto J Sarni, Maria Eduarda A Tavares, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
Donald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
Scientific Reports
|
August 3, 2017
Structural and functional identification of vasculogenic mimicry in vitro
Dusan Racordon, Andrés Valdivia, Gabriel Mingo, et al.
Clinical and Experimental Pharmacology & Physiology
|
October 30, 2024
Short-term exercise counteracts accelerated ageing impacts on physical performance and liver health in mice
Ana P Pinto, Vitor R Muñoz, Maria Eduarda A Tavares, et al.
Journal of Cellular Physiology
|
March 12, 2014
Independent anti-angiogenic capacities of coagulation factors X and Xa
Soledad Lange, Ibeth Gonzalez, Mauricio P Pinto, et al.
Page
of 72